Taxanes: Old drugs, new oral formulations

European Journal of Pharmacology

Volumn 717, Issue 1-3, 2013, Pages 40-46

  Jibodh, Rajni A ^a   Lagas, Jurjen S ^b   Nuijen, Bastiaan ^b   Beijnen, Jos H ^b,c   Schellens, Jan H M ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cytochrome P450; Docetaxal; Oral; P glycoprotein; Paclitaxel; Ritonavir

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; DOCETAXEL; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RITONAVIR; TAXANE DERIVATIVE; VALSPODAR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVANCED CANCER; AREA UNDER THE CURVE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER RESISTANCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STORAGE; DRUG UPTAKE; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE DISCOMFORT; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

CYTOCHROME P450; DOCETAXAL; ORAL; P-GLYCOPROTEIN; PACLITAXEL; RITONAVIR;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CYTOCHROME P-450 CYP3A; HUMANS; P-GLYCOPROTEIN; TAXOIDS;

EID: 84885948345     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.02.058     Document Type: Review

References (30)

1. G.L. Amidon, H. Lennernäs, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. H.A. Bardelmeijer, M. Ouwehand, J.H. Beijnen, J.H.M. Schellens, and O. van Tellingen Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice Invest. New Drugs 22 2004 219 229 (Pubitemid 39012561)
3. H.A. Bardelmeijer, M. Ouwehand, T. Buckle, M.T. Huisman, J.H.M. Schellens, J.H. Beijnen, and O. van Tellingen Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir Cancer Res. 62 2002 6158 6164 (Pubitemid 35244466)
4. W.M. Bennett, A. DeMattos, M.M. Meyer, T. Andoh, and J.M. Barry Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy Kidney Int. 50 1996 1089 1100 (Pubitemid 26342797)
5. P. Borst, and R.O. Elferink Mammalian ABC transporters in health and disease Annu. Rev. Biochem. 71 2002 537 592 (Pubitemid 34800230)
6. J. Crown, and M. O'Leary The taxanes: an update Lancet 355 2002 1176 1178 (Pubitemid 30172946)
7. S.M. Flechner, W.D. Payne, C. van Buren, R. Kerman, and B.D. Kahan The effect of cyclosporine on early graft function in human renal transplantation Transplantation 36 1983 268 272 (Pubitemid 13002674)
8. H.H. Helgason, C.M. Kruijtzer, A.D. Huitema, S.G. Marcus, W.W. ten Bokkel Huinink, M.E. Schot, J.H. Schornagel, J.H. Beijnen, and J.H.M. Schellens Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer Br. J. Cancer 95 2006 794 800 (Pubitemid 44498092)
9. S.L. Koolen, R.A. van Waterschoot, O. van Tellingen, A.H. Schinkel, J.H. Beijnen, J.H.M. Schellens, and A.D. Huitema From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies J. Clin. Pharmacol. 52 2012 370 380
10. G.N. Kumar, A.D. Rodriques, A.M. Buko, and J.F. Denissen Cytochrome P450 mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J. Pharmacol. Exp. Ther. 277 1996 423 431 (Pubitemid 27169089)
11. I.E. Kuppens, T.M. Bosch, M.J. van Maanen, H. Rosing, A. Fitzpatrick, J.H. Beijnen, and J.H.M. Schellens Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093) Cancer Chemother. Pharmacol. 55 2005 72 78 (Pubitemid 40064498)
12. J.S. Lagas, M.L. Vlaming, O. van Tellingen, E. Wagenaar, R.S. Jansen, H. Rosing, J.H. Beijnen, and A.H. Schinkel Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics Clin. Cancer Res. 12 2006 6125 6132 (Pubitemid 44703778)
13. C.G.L. Lee, M.M. Gottesman, C.O. Cardarelli, M. Ramachandra, K.T. Jeang, S.V. Ambudkar, I. Pastan, and S. Dey HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter Biochemistry 37 1998 3594 3601 (Pubitemid 28162914)
14. M.M. Malingré, J.H. Beijnen, and J.H.M. Schellens Oral delivery of taxanes Invest. New Drugs 19 2001 155 162 (Pubitemid 32423720)
15. M.M. Malingré, J.M. Terwogt, J.H. Beijnen, H. Rosing, F.J. Koopman, O. van Tellingen, K. Duchin, W.W. ten Bokkel Huinink, M. Swart, J. Lieverst, and J.H.M. Schellens Phase I and pharmacokinetic study of oral paclitaxel J. Clin. Oncol. 18 2000 2468 2475 (Pubitemid 30415834)
16. M.M. Malingré, D.J. Richel, J.H. Beijnen, H. Rosing, F.J. Koopman, W.W. ten Bokkel Huinink, M.E. Schot, and J.H. Schellens Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel J. Clin. Oncol. 19 2001 1160 1166 (Pubitemid 32176294)
17. M.M. Malingré, J.H.M. Schellens, O. van Tellingen, H. Rosing, F.J. Koopman, K. Duchin, W.W. ten Bokkel Huinink, M. Swart, and J.H. Beijnen Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration Anticancer Drugs 11 2000 813 820
18. J.M. Meerum Terwogt, M.M. Malingré, J.H. Beijnen, W.W. ten Bokkel Huinink, H. Rosing, F.J. Koopman, O. van Tellingen, M. Swart, and J.H.M. Schellens Coadministration of oral cyclosporin A enables oral therapy with paclitaxel Clin. Cancer Res. 5 1999 3379 3384
19. J.J. Moes, S.L. Koolen, A.D. Huitema, J.H.M. Schellens, J.H. Beijnen, and B. Nuijen Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) Int. J. Pharm. 420 2011 244 250
20. B. Nuijen, M. Bouma, J.H.M. Schellens, and J.H. Beijnen Progress in the development of alternative pharmaceutical formulations of taxanes Invest. New Drugs 19 2001 143 153 (Pubitemid 32423719)
21. R.L. Oostendorp, A. Huitema, A. Rosing, R.S. Jansen, R. ter Heine, M. Keessen, J.H. Beijnen, and J.H.M. Schellens Coadministration of ritonavir strongly enhances theapparent oral bioavailability of docetaxel in patients with solid tumors Clin. Cancer Res. 15 2009 4228 4233
22. EK. Rowinsky The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents Annu. Rev. Med. 48 1997 353 374 (Pubitemid 27101837)
23. J.H.M. Schellens, M.M. Malingre, C.M. Kruijtzer, H.A. Bardelmeijer, O. van Tellingen, A.H. Schinkel, and J.H. Beijnen Modulation of oral bioavailability of anticancer drugs: from mouse to man Eur. J. Pharm. Sci. 12 2000 103 110
24. A.H. Schinkel, U. Mayer, E. Wagenaar, C.A. Mol, L. van Deemter, J.J. Smit, M.A. van der Valk, A.C. Voordouw, H. Spits, O. van Tellingen, J.M. Zijlmans, W.E. Fibbe, and P. Borst Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins Proc. Nat. Acad. Sci. USA 94 1997 4028 4033 (Pubitemid 27180493)
25. A.H. Schinkel, J.J. Smit, O. van Tellingen, J.H. Beijnen, E. Wagenaar, L. van Deemter, C.A. Mol, M.A. van der Valk, E.C. Robanus Maandag, H.P. te Riele, A.J.M. Berns, and P. Borst Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 1994 491 502 (Pubitemid 24153990)
26. A. Sparreboom, J. van Asperen, U. Mayer, A.H. Schinkel, J.W. Smit, D.K. Meijer, P. Borst, W.J. Nooijen, J.H. Beijnen, and O. van Tellingen Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine Proc. Nat. Acad. Sci. USA 94 1997 2031 2035 (Pubitemid 27113956)
27. J. van Asperen, O. van Tellingen, A. Sparreboom, A.H. Schinkel, P. Borst, W.J. Nooijen, and J.H. Beijnen Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833 Br. J. Cancer 76 1997 1181 1183 (Pubitemid 27448014)
28. J. van Asperen, O. van Tellingen, M.A. van der Valk, M. Rozenhart, and J.H. Beijnen Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A Clin. Cancer. Res. 4 1998 2293 2297 (Pubitemid 28477891)
29. A.E. van Herwaarden, R.A. van Waterschoot, and A.H. Schinkel How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol. Sci. 30 2009 223 227
30. A.E. van Herwaarden, E. Wagenaar, C.M. van der Kruijssen, R.A. van Waterschoot, J.W. Smit, J.W. Song, M.A. van der Valk, O. van Tellingen, J.W. van der Hoorn, H. Rosing, J.H. Beijnen, and A.H. Schinkel Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism J. Clin. Invest. 117 2007 3583 3592 (Pubitemid 350097013)